# Immune Modulation Therapy for Pompe Disease

> **NCT02525172** · PHASE4 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 8 (estimated)

## Conditions studied

- Pompe Disease

## Interventions

- **DRUG:** Rituximab
- **DRUG:** intravenous immune globulin
- **DRUG:** Bortezomib
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02525172
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2016-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525172, "Immune Modulation Therapy for Pompe Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02525172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*